Core Insights - Robotic-assisted surgery is becoming essential in modern healthcare, with Intuitive Surgical and Stryker leading the market [1][2] - Both companies are heavily investing in innovation and global expansion, making them attractive for investors [2] Market Position and Differentiation - Intuitive Surgical pioneered robotic surgery with the da Vinci platform, while Stryker entered the market through the acquisition of Mako Surgical [3] - Intuitive holds nearly 80% of global surgical robotics volume, contrasting with Stryker's focus on orthopedic robotics with over 1.5 million Mako procedures [4] Revenue & Growth Trends - Intuitive's Q1 2025 revenues increased by 19% to $2.25 billion, with da Vinci procedures growing by 17% [5] - Stryker's MedSurg/Neurotechnology sales rose by 10.6% to $3.89 billion in Q4 2024, while Orthopaedics climbed by 10.8% to $2.55 billion [5] - The global robotic surgery market is projected to grow at a CAGR of 16.5% through 2029, driven by minimally invasive trends and aging populations [6] Estimates Comparison for ISRG & SYK - Zacks Consensus Estimate for ISRG's fiscal 2025 sales and EPS implies a year-over-year improvement of 15.6% and 7.1% respectively [7] - Zacks Consensus Estimate for Stryker's 2025 sales and EPS implies a year-over-year improvement of 8.6% and 10.4% respectively [10] Innovation Driving Growth - Intuitive Surgical is investing in next-generation platforms like the Ion endoluminal system for robotic bronchoscopy [12] - Stryker is enhancing its Mako SmartRobotics suite with AI-driven 3D CT planning and AccuStop haptic feedback [13] Price Performance & Valuation - Year-to-date price performance shows ISRG shares have lost 1.5%, while SYK shares have gained 1.8% [15] - Intuitive Surgical's dominance and sustainable revenue growth position it well, while Stryker's innovations fuel growth in the joint-replacement robotics niche [17] Zacks Rank & Style Score - Both companies currently hold a Zacks Rank 3 (Hold), complicating the investment decision [18] - ISRG's style score of 'F' indicates expensive valuation and low growth potential, while SYK's style score of 'C' suggests strong growth prospects [19]

Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the launch of the ReWalk 7 Personal Exoskeleton, which was released for sales in the U.S. earlier this month MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global lead ...

Core Insights - Sequel Med Tech and Senseonics have announced a commercial development agreement to integrate the twiist Automated Insulin Delivery (AID) System with Senseonics' Eversense 365 CGM system, making it the first AID system compatible with a one-year CGM [2][3][5] - The integration aims to enhance diabetes management for individuals with type 1 diabetes by providing more tools for glucose control, convenience, and personalization [3][5] - The twiist AID System is designed to automatically adjust insulin delivery based on real-time sensor readings, offering flexibility in diabetes management [6][8] Company Overview - Sequel Med Tech is focused on developing innovative insulin delivery technologies and aims to simplify disease management through advanced systems [8] - Senseonics specializes in long-term implantable glucose monitoring systems, with the Eversense 365 being the only implantable CGM that offers continuous monitoring for up to one year [9][11] - The collaboration between Sequel and Senseonics represents a significant advancement in diabetes care, providing users with a comprehensive solution that combines advanced pump, algorithm, and sensor technologies [4][5] Product Details - The twiist AID System is FDA-cleared for individuals aged six and up with type 1 diabetes, allowing for precise insulin delivery tailored to individual needs [6] - Eversense 365 received FDA clearance as an integrated continuous glucose monitoring system, enabling its use within automated insulin delivery systems [5][10] - The integration of twiist and Eversense 365 is expected to be commercially available in Q3 2025, enhancing the options available for diabetes management [5][6]

Core Viewpoint - Revvity, Inc. reported strong first-quarter 2025 results with adjusted EPS of $1.01, exceeding estimates and showing year-over-year improvement [1][9] Financial Performance - Adjusted EPS of $1.01 beat the Zacks Consensus Estimate of 96 cents by 5.2% and improved 3.1% from the previous year [1] - Revenues reached $664.7 million, up 2.3% year over year and 4% organically, surpassing the Zacks Consensus Estimate by 0.4% [2] - GAAP EPS from continuing operations was 35 cents, compared to 21 cents in the prior-year period [1] Segment Analysis - Life Sciences segment revenues totaled $340 million, up 2% organically from the previous year, with adjusted operating income of $106 million, a 5% increase [3] - Diagnostics segment revenues were $324 million, reflecting a 3% year-over-year increase, with a 5% organic growth [3] Margin and Expense Analysis - Selling, general and administrative expenses were $249.7 million, down 4.2% year over year, while research and development expenses were $53.6 million, down 6.4% [5] - Adjusted operating income improved 2.5% to $169.9 million, with an adjusted operating margin of 25.6%, expanding 10 basis points [5] Financial Position - Cash and cash equivalents at the end of Q1 2025 were $1.14 billion, slightly down from $1.16 billion at the end of the previous quarter [6] - Net cash used in operating activities was $134.1 million, compared to $150.1 million in the year-ago quarter [6] 2025 Guidance - The company reiterated its earnings outlook, expecting adjusted EPS in the range of $4.90-$5.00, and updated revenue guidance to $2.83-$2.87 billion [7] - The previous revenue guidance was $2.80-$2.85 billion, with the Zacks Consensus Estimate for EPS and revenues at $4.93 and $2.82 billion, respectively [7] Market Reaction and Outlook - Shares of RVTY rose 5.9% in pre-market trading, although the stock has declined 14.6% year-to-date compared to the industry's 1.6% decline [9] - The company is well-positioned to navigate challenges and capitalize on opportunities, with solid execution across both segments [10] Recent Developments - The launch of EUROIMMUN's Anti-Measles Virus ELISA 2.0 in Europe is expected to drive additional sales [11] - FDA approval for the Auto-Pure 2400 liquid handling platform with the T-SPOT.TB test will facilitate commercialization in the U.S. market [12]

三轴全向踝关节康复机械人，拍摄：实习生莫林衛 蔡璟补充道，这些丰富的医疗数据为人工智能模型的开发提供了宝贵的资源，香港可以充分利用内地的 医疗数据优势，在人工智能模型开发过程中更好地实现技术落地与应用。通过充分利用内地的医疗数 据，企业能够开发出更具针对性和实用性的产品，更好地满足市场需求。这种优势不仅为香港的科技企 业带来了发展机遇，也为全球医疗科技的发展提供了新的思路和方向。 蔡璟团队研发的人工智能系统，可自动分析患者CT影像生成肺部功能影像，并通过"功能引导"放射治 疗技术设计个性化方案，降低对高功能区域的放射损伤。该系统采用尖端算法训练模型，兼容主流放疗 设备，目前正在香港和内地医院开展临床测试，并计划扩展至肝脑肿瘤治疗。 本次分享会上，香港理工大学武汉科技创新研究院院长何明光带来了其团队的最新成果，该产品创新应 用生成式AI，仅凭普通眼底照片即可生成高精度血管造影影像，该产品现于粤港澳大湾区顶尖机构进 行多中心试验；南京技术创新研究院院长张丹则带来了其团队首创的三轴全向踝关节康复机械人，该设 备正与上海华山医院合作临床测试，未来将结合AI提供个性化方案，并拟扩展至肩手关节康复领域。 蔡璟团队研发的自 ...

Core Insights - Medtronic announced positive clinical outcomes from studies on atrial fibrillation (AFib) patients using the Affera™ technologies, including the Sphere-360™ and Sphere-9™ catheters [1][6] Group 1: Sphere-360 Study - The Sphere-360 catheter demonstrated an 88% freedom from arrhythmia recurrence and 98% durable pulmonary vein isolation (PVI) in a one-year study [2] - No safety events were reported in the subgroup treated with the optimized waveform, highlighting the safety profile of the Sphere-360 [2] - The Sphere-360 catheter features a conformable lattice design and is integrated with the Affera Mapping and Ablation System, utilizing the smallest sheath in single-shot PFA technology at 8.5 Fr [2][3] Group 2: Sphere-9 Catheter - The Sphere-9 catheter was shown to safely create linear lesions in persistent AF patients, enhancing the chances of restoring normal heart rhythm [4] - This catheter is part of the Affera system, which received FDA approval in October 2024, indicating its efficacy in persistent AF treatment [4] Group 3: Medtronic's Position and Future Plans - Medtronic plans to initiate a U.S. pivotal trial for the Sphere-360 catheter later in the year, indicating ongoing commitment to innovation in AFib treatment [3] - The company is the only one offering two PFA solutions, with the PulseSelect™ system already available in over 30 countries, showcasing its leadership in the electrophysiology market [5] - Medtronic continues to expand the Affera system's availability globally, with current access in Europe, Australia, and New Zealand [5]

"以前要坐车去城里的医院，现在家门口就能查，很方便！"近日，在武夷山市兴田镇汀前村，65岁的村 民王阿妹通过鹰瞳科技AI眼底相机，仅用15秒便完成了眼底扫描。3分钟后，系统生成报告提示其右眼 存在糖尿病性视网膜病变高风险。随后，她收到武夷山市立医院的转诊通知，第一时间接受治疗。这一 幕，正是武夷山市推进全民健康网格化服务、深化医防融合、借助科技赋能基层医疗的缩影。 AI赋能下沉，织密慢性病防控网 自今年3月起，武夷山市依托"健康武夷·慢病一体化管理平台"，启动2025年度65岁以上老年人及重点人 群免费健康体检工作，新增糖化血红蛋白检测和AI眼底筛查两个项目，构建起糖尿病、视网膜病变等 慢性病的"筛查-预警-干预"闭环体系。截至4月上旬，全市已为2228名糖尿病患者完成糖网、青光眼等 致盲性眼底疾病筛查，累计检出高风险病例296例，为患者争取了宝贵的救治时间窗。 "糖化血红蛋白能反映近3个月血糖控制水平，眼底血管状况则关联全身血管健康。"武夷山公立总医院 党委副书记、院长林清飞介绍，AI设备一次拍摄可同步完成糖网病变、青光眼筛查及动脉硬化风险评 估，极大提升了基层诊疗效率。 注：图文内容采编自武夷山市立医院公 ...

The Sustainability Report provides data for 2022 through 2024 on the Company’s environmental, social, and governance initiativesMENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company’s sustainability activities, performance and res ...

Aclarion (ACON) Conference Call Summary Company Overview - Aclarion focuses on addressing chronic low back pain, a significant healthcare issue in the United States and globally [1] - The company has a strong financial position with nearly $14.6 million in cash, zero debt, and is fully compliant with NASDAQ requirements [2][26] Industry Context - Chronic low back pain affects approximately 266 million people worldwide, making it the leading cost ailment in healthcare [3][4] - In the U.S., there are 635,000 spinal fusion surgeries annually, with high costs averaging $58,000 for one-level and $71,000 for two-level procedures [4] - Surgical success rates are low, with only 48-54% achieving success, and 80% of patients experiencing discomfort post-surgery [4][5] Market Opportunity - The initial addressable market for Aclarion's product, NOSI Scan, is estimated at $6.03 billion based on the fusion and disc replacement market [6] - The potential revenue increases significantly when considering other spine procedures and chiropractic care [7] Product and Technology - NOSI Scan utilizes spectroscopy to measure pain biomarkers and structural integrity within spinal discs, providing a non-invasive diagnostic alternative to traditional methods [9][12] - The technology is patented with over 40 patents worldwide, covering various aspects of the product and its application [13] Clinical Evidence and Trials - Aclarion is conducting a national randomized controlled trial called CLARITY, which is fully funded at $4.6 million, to provide robust evidence for the efficacy of NOSI Scan [3][16] - Previous studies indicate that 85% of patients improved when treated based on NOSI Scan results, compared to 63% without treatment [15][16] Regulatory and Market Strategy - The company has secured payer approvals in the UK, covering over 5.2 million people, and is working to expand its market presence [17][19] - Aclarion aims to transition its CPT codes from category three to category one to facilitate reimbursement in the U.S. [20] Management Team - The management team has extensive experience in healthcare and technology, with zero turnover since the IPO [21][24] - Key team members include a board-certified neurosurgeon and executives with backgrounds in major healthcare companies [22][24] Challenges and Future Outlook - The introduction of new technology into the payer community is challenging and requires tactical efforts to gain acceptance [34] - Aclarion is focused on building KOL advocacy and societal support to overcome reimbursement barriers [33][34] Key Takeaways - Aclarion is positioned to address a significant healthcare issue with a unique, non-invasive diagnostic tool that has strong market potential [25] - The company is well-funded and has a clear roadmap for expanding its commercial footprint and driving payer acceptance [26][27]

Financial Data and Key Metrics Changes - First quarter revenue was $2.25 billion, a 19% increase year over year, with constant currency growth at 20% [29][30] - Pro forma gross margin for Q1 was 66.4%, down from 67.6% in the same quarter last year, primarily due to higher facility costs and a mix of newer products [34] - Pro forma net income for Q1 was $662 million, or $1.81 per share, compared to $541 million, or $1.50 per share, in the prior year [37] Business Line Data and Key Metrics Changes - Da Vinci procedure growth was 17% in Q1, with significant strength in general surgery in the US and notable performance in India and Korea [9][26] - Capital placements included 367 da Vinci systems, a 17% increase from the previous year, with 147 being da Vinci V systems [10][27] - ION procedures grew 58% to approximately 31,000 in the quarter, with 49 ION systems placed [32] Market Data and Key Metrics Changes - US procedures grew 13%, driven by benign general surgery, while OUS procedures grew 24%, led by India and Korea [26][78] - Procedure growth in China improved from the prior quarter, primarily driven by urologic procedures [26] - The installed base of da Vinci systems grew 15% year over year [25] Company Strategy and Development Direction - The company aims to assure product supply globally and optimize production costs amid dynamic trade policies [7][8] - Focus on the full launch of da Vinci V and increasing adoption of focused procedures through training and market access efforts [19][20] - Commitment to building industrial scale, product quality, and manufacturing optimization [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in procedure growth, raising the full-year 2025 procedure growth forecast to 15% to 17% [39] - The impact of tariffs is expected to add approximately 1.7% to cost of sales, with a potential increase in impact as the year progresses [24][41] - Management remains cautious about the capital environment, noting potential constraints in key OUS markets due to government budget limitations [48][80] Other Important Information - The company opened new manufacturing facilities in California to expand its US manufacturing and R&D footprint [35] - The average selling price for da Vinci systems increased to $1.62 million, driven by a higher mix of da Vinci V placements [31] - The company is focused on enhancing its digital tools and computational capabilities to support surgical performance [17] Q&A Session Summary Question: Impact of tariffs on financials - Management indicated that approximately half of the tariff impact is related to US-China trade, with the remainder from imports into the US from other countries [45] Question: Capital environment and customer response - Management noted strong customer response to da Vinci V in the US, with leasing arrangements providing flexibility amid capital constraints [48] Question: OUS growth drivers - Management highlighted strong growth in early-stage markets like India and Taiwan, with ongoing efforts to engage key opinion leaders and surgical societies [80]